Rasagiline for the treatment of Parkinsons disease: An update

Fabrizio Stocchi, Chiara Fossati, Margherita Torti

Research output: Contribution to journalArticlepeer-review


Introduction: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain. It has been demonstrated that rasagiline can improve motor and some non-motor symptoms (NMS) in both early and advanced Parkinsons disease (PD) patients, and it also exhibits neuroprotective and antiapoptotic properties.Areas covered: The objective of this review, performed by a Medline search on the most recent papers investigating the therapeutic effects of rasagiline, is to describe the role of rasagiline in the schedule of treatment of early and advanced PD patients. It will then focus on its role in treating NMS, fatigue, early morning off and cognitive decline, which heavily affect quality of life for PD patients.Expert opinion: Rasagiline is an efficacious, well-tolerated, easy to use drug. The drug has been extensively studied and has proven its efficacy in monotherapy and in combination with any other antiparkinsonian therapy. It proved to be efficacious in reducing off time and in improving early morning off but also some NMS, thus enhancing the therapeutic approach to PD.

Original languageEnglish
Pages (from-to)2231-2241
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Issue number14
Publication statusPublished - Sept 22 2015


  • early morning akinesia
  • fatigue
  • levodopa
  • monoamine oxidase-B inhibitors
  • motor fluctuations
  • non-motor symptoms
  • Parkinson's disease
  • rasagiline

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)


Dive into the research topics of 'Rasagiline for the treatment of Parkinsons disease: An update'. Together they form a unique fingerprint.

Cite this